Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03865290
Other study ID # 18-005041
Secondary ID P01DK068055
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 2, 2019
Est. completion date March 2026

Study information

Verified date May 2024
Source Mayo Clinic
Contact Kelly J Feuerhak
Phone 507-255-6802
Email Feuerhak.Kelly@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.


Description:

The primary objectives of this study are to evaluate the effects of ondansetron, on symptoms (i) during a gastric emptying study, (ii) during enteral lipid infusion and (iii) in daily life.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date March 2026
Est. primary completion date March 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Healthy male or non-pregnant, non-breastfeeding female volunteers; - 18-75 years old; - Able to provide written informed consent before participating in the study - Able to communicate adequately with the investigator and to comply with the requirements for the entire study; including the willingness and ability to consume the components of the test meals - Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting, regurgitation) - Patients in the DM group will also require Type 1 or 2 DM of = 3 years duration; in patients with type 2 DM, the dyspepsia symptoms should have begun or worsened after DM was diagnosed Exclusion Criteria: - Major abdominal surgery (i.e., appendectomy, cholecystectomy, tubal ligation, hysterectomy, herniorrhaphy, and limited colonic resection are permissible) - Clinical evidence (including physical exam and EKG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns - Current use of opiates, alpha adrenergic agonists, metoclopramide, monoamine oxidase inhibitors, more than one serotonergic medication, and high doses of anticholinergic agents (eg, amitriptyline greater than 50 mg daily). If medically safe, these drugs may be discontinued for four half lives prior to study assessments. - Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect central processing of pain - Bleeding or clotting disorders or medications that increase risk of bleeding from mucosal biopsies - Positive tissue transglutaminase antibodies (TTG), - Pregnant or breast-feeding females - Known intolerance or allergy to eggs - Poor peripheral venous access, if central venous access is not available - Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study - History of Long QT Syndrome or prolonged QT interval (i.e., corrected QT interval > 480 ms) - Current symptoms of a functional gastrointestinal disorder assessed by questionnaire - Severe vomiting that would preclude tube placement or participation in the study - Structural cause for symptoms by endoscopy within the past 12 months - Patients with gastric pacemakers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ondansetron 8mg
Oral Ondansetron 8 mg
Placebo
Oral matched placebo

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in severity of symptoms during enteral infusion Visual analog scale (VAS) used to measure the change in symptom severity with a scale of 0=absent, 1=light, 2=moderate, 3=severe, 4=intolerable baseline, every 15 minutes up to 8 hours
Primary Change in severity of symptoms during gastric emptying study Visual analog scale (VAS) used to measure the change in symptom severity with a scale of 0=absent, 1=light, 2=moderate, 3=severe, 4=intolerable baseline, every 15 minutes up to 2 hours
Primary Change in severity of daily symptoms Gastroparesis Cardinal Symptom Index - Daily Diary (GCSI-DD) used to measure the change in symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe Baseline, daily for six weeks
Primary Change in severity of gastrointestinal symptoms Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) used to measure the change in symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe Baseline, 2 weeks, 6 weeks
Primary Change in severity of gastrointestinal symptoms effect on Quality of Life Gastrointestinal Disorders - Quality of Life and Well-Being (PAGI-QOL) used to measure the change in symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe Baseline, 2 weeks, 6 weeks
Primary Change in effect of Gastrointestinal symptoms on Quality of Life Nepean Dyspepsia Index used to measure symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe Baseline
Secondary Glucose level Compare the changes in glucose level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Insulin level Compare the changes in insulin level during a lipid infusion baseline, approximately 60-120 minutes
Secondary C-peptide level Compare the changes in C-peptide level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Glucagon-like Peptide 1 (GLP-1) Compare the changes in Glucagon-like Peptide 1 (GLP-1) level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Cholecystokinin (CCK) Compare the changes in Cholecystokinin (CCK) level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Ghrelin Compare the changes in Ghrelin level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Peptide YY (PYY) Compare the change in Peptide YY (PYY) level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Plasma Compare the change in plasma level during a lipid infusion baseline, approximately 60-120 minutes
Secondary Effect of gastrointestinal symptoms on Quality of Life - Nepean Dyspepsia index Score is derived from 25 items pertaining to QOL Baseline
Secondary Severity of gastrointestinal symptoms - Nepean Dyspepsia index Nepean Dyspepsia Index is used to measure symptom severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe Baseline
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A